GoldenGolden

Shire (company)

Shire is a United Kingdom-based company.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 4, 2021
BioSpace
Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Douglas Kerr, M.D., Ph.D., to its board of directors.
Amirah Al Idrus
March 18, 2021
FierceBiotech
Mark Rus, formerly Shire's group vice president of neuroscience, is taking the helm at Delix Therapeutics, a biotech developing drugs that target neuroplasticity to treat central nervous system disorders. He arrives at Delix after a stint at Atlas Venture, where he led work on an early-stage, neuropsychiatry startup as an entrepreneur in residence.
Michael O'Neill
February 18, 2021
Business Insider
The 240-year old biopharma company reinforced its global ambition in 2019 with the $62 billion acquisition of pharma firm Shire
Research and Markets
February 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Dry Eye Medication Global Market Report 2020-30: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering....
Amirah Al Idrus
January 25, 2021
FierceBiotech
Faze Medicines has a new CEO: Philip Vickers, Ph.D., a Shire alum who most recently led cancer-focused Northern Biologics. Vickers takes over from interim CEO Cary Pfeffer six weeks after Faze emerged with $81 million to pursue medicines targeting biomolecular condensates.
Jarrod Lucas
October 9, 2019
ABC News
Residents in one of Australia's most famous gold rush towns are divided over plans to explore for the precious metal beneath its streets, amid record prices for gold which have injected new life into Coolgardie.
Diane Bartz
Invalid Date
U.S.
An appeals court on Monday upheld a judge's decision dismissing a lawsuit filed by the U.S. Federal Trade Commission to fight the practice of brand-name drug companies using a government petition system to delay cheaper, generic drugs from coming to market.
January 8, 2019
WebWire
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) ("Takeda") today announced the completion of its acquisition of Shire plc ("Shire"), becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions with dedicated employees worldwide. Takeda's R&D efforts are focused on...
Takashi Umekawa
Invalid Date
U.S.
Takeda Pharmaceutical <4502.T> shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt.
Ben Hirschler
November 5, 2018
U.S.
The boss of Japan's Takeda Pharmaceutical <4502.T> said on Monday he was confident of securing investor backing for its $62 billion acquisition of London-listed Shire , despite some shareholders' fears about the resulting debt burden.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.